http://zinc.docking.org Table S1 : Small molecule databases. Here we provide links to several small molecule structure and/or bioactivity databases that can potentially be used with bioassayR. This list is not comprehensive.
Drug-target space analysis
To assess the diversity of the protein target space represented by PubChem BioAssay, we enumerated its small molecules and protein targets with bioassayR. Small molecules were grouped into FDA approved drugs and all other compounds, and protein targets were organized by GO slim terms of the Molecular Function Ontology ( Figure S1 ) 15 . The PubChem BioAssay data was used to produce a compound-target matrix as described in the "bioassaySet object" section of the manuscript. To highlight the relative distribution of potentially novel compounds in the data, the GO slim terms are ordered in Figure S1 according to decreasing numbers of active FDA approved drugs.
As expected, a larger fraction of FDA approved drugs exhibit activity against proteins annotated with GO slim terms than is the case for non-drug compounds. Importantly, a substantial number of active nondrug compounds has been identified within each GO category. Some categories (such as GTPase) have very few FDA approved active drugs, but a large quantity of active non-drug compounds. The FDA approved drugs show activity against 1789 protein targets, whereas the non-drug compounds show activity against an additional 3020 protein targets. Of these 3020 additional targets, 901 are substantially distinct both from one another and any of the FDA approved drug targets at the amino-acid sequence level based on the kClust clustering described in the "Prebuilt PubChem BioAssay Database" section of the manuscript. This is a marked expansion of the protein target space currently covered by FDA approved drugs, illustrating the utility of these data for identifying drug candidates with unique properties potentially relevant for the development of medical treatments.
Clustering drugs by structure and bioactivity profile
Using the bioactivity clustering features described in the manuscript, we used bioassayR to cluster all FDA approved drugs screened against at least 10 distinct targets in the PubChem BioAssay data. For the resulting 895 compounds meeting this requirement, we generated a binary HTSFP with the bioactivityFingerprint function, with a length of 2019 bits, each representing a screened protein target. While bioassayR supports continuous z-score HTSFPs, binary HTSFPs were chosen for this example to incorporate data from assays provided with activity categories but without continuous numeric scores. ChemmineR was then used to produce a distance matrix based on the Tanimoto similarity coefficient. The distances were used to project each compound into two dimensional plane with MDS ( Figure S2 ) where the points are spaced proportionally to the similarity among the bioactivity profiles of each compound 16 . A small random position jitter was applied to minimize overlap of closely spaced points. To assess whether the compounds within bioactivity clusters share structural similarities, the same compounds have also been clustered by structural similarity with functionalities provided by ChemmineR. This structural clustering employed atom pair fingerprints for structure comparisons, the Tanimoto coefficient as similarity metric and single linkage hierarchical clustering with tree cutting at 0.6 to partition the compounds into discrete similarity groups.
The results in Figure S2 show several discrete groupings of drugs by bioactivity, while others appear The number of compounds with activity or inactivity against at least one target protein within each protein class is plotted on the horizontal axis. The plot on the left gives the numbers for FDA approved drugs, the one in the center for all other compounds, and the one on the right gives the numbers of the corresponding protein targets included in the assays. To distinguish between small and zero quantities of active compounds, the active point is omitted for GO slim terms which have no active compounds.
more evenly dispersed across the plane. To compare the results with the outcome of the structure-based clustering, a subset of the structural clusters have been highlighted with distinct colors. Dots with identical colors in close proximity identify groups of compounds sharing both similar structure and bioactivity patterns. However, exceptions are common, where compounds of similar structure are not located in close proximity. This separation can be due to two main reasons: (i) true biological differences in their target binding profiles and/or (ii) a deflation of the similarity coefficients of compound pairs caused by sparseness in their bioactivity profiles. The latter false negatives are a common problem in bioactivity data that has been discussed in the manuscript as well as in previous studies 17 . The results in Figure S2 illustrate how analyzing bioactivity data with bioassayR provides additional information that cannot reliably be inferred from structural similarity alone. This includes the systematic identification of both structurally distinct compounds with similar bioactivity profiles, as well as compounds with similar structure but distinct bioactivity.
Guiding high-content screens with reference data from single target bioassays Single protein target bioassay data can serve as a reference for guiding and interpreting various aspects of high-content screens. For instance, they can be used to assemble small molecule screening libraries enriched in bioactives targeting a biological process of interest. This can be important for low-throughput assays where testing a large number of compounds is not an option. In addition, single target bioassay data can guide the often very time consuming process of identifying target sites in high-content screens. The following illustrates with an example how bioassayR can facilitate these tasks.
The high-content screen chosen for this example is PubChem BioAssay #465 entitled "Primary HTS Distance matrix 2D distance coordinates (MDS) Figure S2 : Clustering small molecules by structure and bioactivity profile. Multidimensional scaling (MDS) was used to embed small molecules into a two dimensional space (x-and y-axis). Each point represents an FDA approved drug. The distance between the points is proportional to the similarity of the bioactivity profile available for each drug. Structure-based clustering results are also indicated by colors for 8 mid-size clusters, while the remaining compounds are shown in grey. The latter clustering used atom pair fingerprints as similarity measure and hierarchical clustering with tree cutting to assign compounds to discrete structure-based similarity groups. Four example compounds are shown, which are members of the same structural cluster (shown here in purple), which is comprised largely of steroid drugs.
assay for chemical inhibitors antigen receptor-induced NF-kappaB activation". It uses a luciferase reporter to measure NF-kappaB activation in HEK-293 cells. This screen includes bioactivity data for 61,605 compounds. It was chosen as a representative among 345 published high-content bioassays containing at least 10,000 tested compounds.
To identify single target PubChem Bioassay data relevant for this screen, we searched the Reactome database for all Homo sapiens entries annotated with either "NF-kB" or "NFkB"
18 . This query returned 1,120 proteins. Of these, we used bioassayR to identify 605 proteins with single target screening data in the PubChem BioAssay database. A binary bioactivity matrix was generated from this data using the bioassayR functions getBioassaySetByCids and perTargetMatrix. One dimension of this matrix represented the 61,605 compounds from bioassay #465 and the other dimension the single target bioactivity data from the 605 proteins associated with NF-kappaB. We then summed the matrix to obtain the number of active targets for each compound.
The high-content assay reported 128 actives out of a total of 61,605 compounds (0.21% activity). Among the single-target assays, 1,749 out of the same 61,605 compounds were found to be active against one to five NF-kappaB related targets. Table S3 summarizes the distribution. Among these 1,749 single-target active compounds, 73 were also active in the high-content assay (4.17% activity). Table S3 : Results of a high-content screen compared to single target bioassays of the same pathway. 1 The numbers of total and active compounds are given for the high-content PubChem BioAssay #465. This assay screened for inhibitors of antigen receptor-induced NF-kappaB activation.
High-Content PubChem
2 The same numbers are given for the subset of compounds that have also been found active in single target assays where the corresponding target protein is associated with NF-kappaB processes. Currently, 605 single target assays meet this requirement. The results are subdivided into the number of compounds active in variable numbers of single target assays including ≥1 and 1-5.
This example demonstrates that including the active compounds from relevant single target assays can substantially enrich high-content screening libraries for active compounds, and thus reduce the total number of compounds that need be tested in primary screening efforts. Additionally, single target bioactivity data provides valuable information as it identified candidate target site(s) for 73 of the 128 actives (57%) present in bioassay #465. This information can reduce time-and labor-intensive target identification processes that are often an integral part of many high-content screening efforts conducted in chemical genomics.
Time performance evaluation
The time performance of bioassayR functions can be divided into two categories: database loading, and database querying. The former is only relevant to users planning to create a custom bioassayDB database file. In the case of database loading, the major performance bottleneck involves parsing raw text files into a machine readable format (using regular expressions internally), and therefore is expected to scale in roughly O(n) (linear) time with the number of compound-target activity results, with limited dependence on the absolute number of assays, targets, and compounds. In the case of database querying, the major performance bottleneck involves searching the database file, which makes use of SQLite hash table indices engineered to match their corresponding bioassayR query functions. In most cases these are expected to scale in roughly O(log n) (logarithmic) time in proportion to the number of distinct compound-target activity results stored in the database. For repeated queries of the same type (such as finding the active targets for each compound in a large compound library), each query will take a similar amount of time. Table S4 reports the total elapsed runtime for seven key bioassayR functions, across compound libraries of size 1, 10, 100, 1000, and 10000. In order, these functions represent the steps of a possible workflow involving loading a bioassayDB database, identifying compounds of interest based on there active targets, and then Table S4 : BioassayR function runtime. Total runtime in seconds for seven key bioassayR functions over the range of 1-10,000 randomly selected compounds. Results generated on a single cpu core of an AMD Opteron 6376 2.3 Ghz processor.
generating and analyzing two types of HTSFPs based on these compounds. These numbers were generated in a single-threaded manner, using one core of a 16 core AMD Opteron 6376 2.3 Ghz processor on a modern rack-mount server running CentOS Linux. Assay parsing and loading statistics were generated by loading subsets of PubChem Bioassay assay aid 360 into an empty database file. The remaining (query based) benchmarks were generated from the full pre-built PubChem BioAssay database, using a random sample of highly screened (at least 10 distinct target assays) compounds. Binary HTSFP searches were performed using the ChemmineR fpSim function 14 . The slowest performing function (getBioassaySetByCids) involves translating bioactivity data from the bioassayDB database file into an in-memory sparse matrix, and is typically only used for a small subset of the available bioactivity data, relevant to a specific analysis. Despite it's runtime, it can be used for a large number of compounds and targets, as it scales with less than linear O(n) time.
While not necessary for most analyses, users can optionally accelerate a large analysis by running bioassayR in parallel across multiple cpu cores by dividing batch queries into equally sized smaller jobs, and executing in parallel using the R library foreach 19 . To enable this, it is preferable for each thread to open it's own read-only access to the same bioassayDB database file, stored on a commonly accessible ramdisk or solid-state hard drive.
